Slide 1: TLANDO (LPCN 1021)
TLANDO® (LPCN 1021) The Convenient Oral Testosterone Replacement Therapy without Titration Requirement
Slide 2: Easy to use and prescribe
Easy to use and prescribe For testosterone replacement therapy Lymphatically ("TRT") in adult Based on proprietary 225 mg testosterone delivers oral males indicated for Lip’ral Technology for undecanoate taken testosterone to avoid conditions associated efficient absorption orally twice daily first
Slide 3: TLANDO: Not Known to Produce Adverse Events Associated with 17-Methylated Testosterone
TLANDO: Not Known to Produce Adverse Events that are Associated with 17- Methylated Testosterone TLANDO METHYL TESTOSTERONE (MT) Transported via Lymph Transported via portal Vein Bypass liver “first pass” effect Prone to liver toxicity Systemic Systemic Circulation Circulation Thoracic Duct Liver Li
Slide 4: Issues with Non-Oral TRT Options
Issues with Non – Oral TRT Options Potential Barrier To Newly Diagnosed and Existing Patients • Black box warning – Secondary exposure to testosterone – Pulmonary oil micro embolism (POME) and anaphylaxis shock • Inconvenient application or painful injection • High incidence of erythrocytosis was re
Slide 5: Persistence Issue with TRTs
Persistence Issue with TRTs High Discontinuation Rates with Products Requiring Titration 100% 90% Androgel 1.62% 80% % Patients Remaining on Topical Therapy New Patients 70% Experienced Patients 60% 50% 40% 30% 20% 10% 0% Y-axis represents percentage of patients in the discontinued group who were 0
Slide 6: TLANDO Attributes
TLANDO® Attributes Convenient Oral Route • No inadvertent transference or pulmonary oil micro embolism risks • Single strength and dose TRT without titration requirement • Enables effective dose at the start of therapy • No “efficacy gap” upon switching from other TRTs • No additional pharmacy a
Slide 7: Differences Between TLANDO and Other Orals
Differences Between TLANDO and Other Orals
Slide 8: Comparative Label Differentiation Summary
Comparative Label Differentiation Summary *plasma ** Subtherapeutic dose to restore hypogonadal patients to eugonadal levels (Thirumalai et al. F1000Res. 2017 Jan 23;6:68.) #Published in Hepatol Commun 2020 Aug 2;4(10):1430-1440 Non-confidential Presentation I 8
Slide 9: TLANDO - FDA-Approved Oral Testosterone Replacement Therapy
TLANDO® - FDA-Approved Oral Testosterone Replacement Therapy Established commercialization partnerships in multiple territories First and only oral testosterone replacement therapy (TRT) • TLANDO® licensed to Verity Pharma for Canada, to Aché for option that does not require dose titration Brazil, t
Slide 10: Business Development Contacts
675 Arapeen Drive, Suite 202 Salt Lake City, Utah-84108 Business Development Contacts Kong Papangkorn, Ph.D. Business Development Manager kp@lipocine.com